Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Balanil Gel is a topical medical device developed by Epitech Group SpA for the symptomatic treatment of inflammatory conditions of the male genital area, such as balanitis and balanoposthitis. The formulation contains adelmidrol, a synthetic ALIAmide (Autacoid Local Inflammation Antagonism) compound that modulates the activity of mast cells and other non-neuronal immune cells to control neuroinflammation and itching. The gel is delivered in a hyaluronan-based bioadhesive matrix designed to bind to mucocutaneous tissue, providing a long-acting effect. Additional ingredients include Echinacea angustifolia extract, phytosphingosine, and biotin, which support skin barrier function and provide antimicrobial properties. Beyond its primary use in genital inflammation, the product is also listed in Epitech's pipeline for broader indications including prostatitis and benign prostatic hyperplasia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Balanil Gel.